Anti-CD20-IL-21 fusokine: the tail wags the dog

Slides:



Advertisements
Similar presentations
Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival by Nathalie A. Johnson, Merrill Boyle, Ali Bashashati, Stephen.
Advertisements

A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies by Jutta Deckert, Peter U. Park,
CD4 T cells: fates, functions, and faults by Jinfang Zhu, and William E. Paul Blood Volume 112(5): September 1, 2008 ©2008 by American Society.
Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas by Amrita Krishnan, Arturo Molina, John Zaia, David.
Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.
Multiple roles of the coagulation protease cascade during virus infection by Silvio Antoniak, and Nigel Mackman Blood Volume 123(17): April 24,
Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors  Sara Charmsaz, Andrew M. Scott,
Uncontrolled Wnt signaling causes leukemia
The beauty of TLR agonists for CTCL
GVHD-associated immunodeficiency: soil or seed?
CD146: a new partner for VEGFR2
Immunotherapy of hepatocellular carcinoma
Dasatinib suppresses in vitro natural killer cell cytotoxicity
Hydroxyurea makes inflammation “just right”?
Collaboration is required for successful immunotherapy
Triple play of H pylori in ITP
Positioning NK-κB in multiple myeloma
by Venetia Bigley, Laura E. Spence, and Matthew Collin
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
When monocyte life hangs by a thread
It's all in the timing by Linda J. Bendall Blood
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
Engineering Natural Killer Cells for Cancer Immunotherapy
by Zhenping Zhu Blood Volume 108(6): September 15, 2006
BTK inhibition in myeloma: targeting the seed and the soil
Tax fingerprint in adult T-cell leukemia
Inherited CalDAG-GEFI deficiency
Heating is a multifunctional adjuvant that affects tumor microenvironment through several intrinsic and extrinsic mechanisms, which could enhance immunotherapy.
FNAIT: the fetus pleads guilty!
Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab)
T regulatory cells turn on T regulatory cells
CMV: when bad viruses turn good
Fusion genes in cord blood
Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion by Yenan T. Bryceson, Michael E. March, Hans-Gustaf.
Deep mining of the RBC proteome
The lazy leukocyte syndrome revisited
Dendritic cells and lymphoma cells: come together right now
Cytokine and chemokine expression of flucloxacillin-specific T cell clones (TCC) of patient P1. Cytokine and chemokine expression of flucloxacillin-specific.
Antigen-induced regulatory T cells
Has the T cell bitten off more than it can chew?
Basophils take a slice of IRF8 pie
Target recognition–induced NK-cell responses
Rare cells predict GVHD
Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index by Chor-Sang Chim, Shing-Yan.
Latest lymphoma classification is skin deep
Lymphoma spread? Target CD47-SIRPα!
Gremlin: vexing VEGF receptor agonist
A recombinant bispecific single-chain antibody, CD19 × CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes by Anja.
by Vladia Monsurrò, Ena Wang, Yoshisha Yamano, Stephen A
by Yuka Nagata, Eisuke Nishida, and Kazuo Todokoro
Annexin and APS: the clot thickens
Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.
Engineering Natural Killer Cells for Cancer Immunotherapy
Combination Therapy Using IL-2 and Anti-CD25 Results in Augmented Natural Killer Cell–Mediated Antitumor Responses  William H.D. Hallett, Erik Ames, Maite.
Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors  Sara Charmsaz, Andrew M. Scott,
The Tim-3 pathway in cancer.
Circulating Natural Killer Lymphocytes Are Potential Cytotoxic Effectors Against Autologous Malignant Cells in Sezary Syndrome Patients  Jean-David Bouaziz,
Donor Selection in T Cell–Replete Haploidentical Hematopoietic Stem Cell Transplantation: Knowns, Unknowns, and Controversies  Stefan O. Ciurea, Richard.
The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity
Cytokine-Induced Memory-Like Differentiation Enhances Unlicensed Natural Killer Cell Antileukemia and FcγRIIIa-Triggered Responses  Julia A. Wagner, Melissa.
Non-CD34+ Cells, Especially CD8+ Cytotoxic T Cells and CD56+ Natural Killer Cells, Rather Than CD34 Cells, Predict Early Engraftment and Better Transplantation.
IL-2– and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets  Sven Létourneau, DPhil, Carsten Krieg, PhD, Giuseppe Pantaleo,
by Christine L. Kempton, and Amanda B. Payne
How I treat Burkitt lymphoma in adults
Influence of the tumor microenvironment on FL
Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma by Bethany Mundy-Bosse, Nathan Denlinger,
Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma
Fire behind the fury: IL-18 and MAS
by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal
Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed.
Presentation transcript:

Anti-CD20-IL-21 fusokine: the tail wags the dog by Stephen M. Ansell Blood Volume 129(16):2209-2210 April 20, 2017 ©2017 by American Society of Hematology

Anti-CD20-IL-21 fusokine. Anti-CD20-IL-21 fusokine. IL-21 conjugated to an anti-CD20 antibody provides 2 additional mechanisms of cytotoxicity. The fusokine binds to CD20+ lymphoma cells and IL-21 signaling has a direct cytotoxic effect on the lymphoma cells. IL-21 also activates intratumoral natural killer (NK) cells and promotes lymphoma-directed cytotoxicity by effector cells. Professional illustration by Somersault18:24. Stephen M. Ansell Blood 2017;129:2209-2210 ©2017 by American Society of Hematology

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.